Cargando…

Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses

Background: Inflammatory markers have been reported to be predictors for the presence of epithelial ovarian cancer (EOC), however, the cut-off value of each marker remains unclear and predictive capability of the markers in different histology types of EOC is still unknown. Methods: A total of 207 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lian, Tian, Jing, Zhang, Liwen, Liu, Luyang, Sheng, Chao, Huang, Yubei, Zheng, Hong, Song, Fengju, Chen, Kexin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040725/ https://www.ncbi.nlm.nih.gov/pubmed/33854628 http://dx.doi.org/10.7150/jca.51642

Ejemplares similares

Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses
por: Eo, Wan Kyu, et al.
Publicado: (2018)

Preoperative Differentiation of Benign and Malignant Non-epithelial Ovarian Tumors: Clinical Features and Tumor Markers
por: Gomes, Tiago Augusto, et al.
Publicado: (2020)

Relative Ratios Enhance the Diagnostic Power of Phospholipids in Distinguishing Benign and Cancerous Ovarian Masses
por: Yagi, Tsukasa, et al.
Publicado: (2019)

Age at menarche and epithelial ovarian cancer risk: A meta‐analysis and Mendelian randomization study
por: Yang, Huijun, et al.
Publicado: (2019)

Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors
por: Winarno, Gatot Nyarumenteng Adhipurnawan, et al.
Publicado: (2023)

Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
por: Shinmura, Hiroki, et al.
Publicado: (2020)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction
por: Koirala, Pratistha, et al.
Publicado: (2020)

Lack of HPV in Benign and Malignant Epithelial Ovarian Tumors in Iran
por: Farzaneh, Farah, et al.
Publicado: (2017)

A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors
por: Ni, Maowei, et al.
Publicado: (2021)

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
por: Furrer, Daniela, et al.
Publicado: (2019)

Comparison of breast cancer risk factors among molecular subtypes: A case‐only study
por: Zhang, Liwen, et al.
Publicado: (2019)

Distinguishing benign from malignant adrenal masses
por: Francis, Isaac R.
Publicado: (2015)

Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study
por: Huang, Chen-Yu, et al.
Publicado: (2020)

LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2016)

Coexistence of Benign Brenner Tumor with Mucinous Cystadenoma in an Ovarian Mass
por: Nazari, Farzaneh, et al.
Publicado: (2020)

Effect of Laparoscopic Ovarian Cystectomy on Ovarian Reserve in Benign Ovarian Cysts
por: Sireesha, Madeti Usharani, et al.
Publicado: (2021)

Prognostic value of preoperative hyponatremia in patients with epithelial ovarian cancer
por: Guo, Jing-Yi, et al.
Publicado: (2019)

Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2022)

Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis
por: Wang, Xin, et al.
Publicado: (2018)

SNPs within microRNA binding sites and the prognosis of breast cancer
por: Zhang, Liwen, et al.
Publicado: (2021)

Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers
por: Sobiczewski, Piotr, et al.
Publicado: (2012)

Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors
por: Zhang, Shuang, et al.
Publicado: (2019)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

Preoperative Predictors of Optimal Tumor Resectability in Patients With Epithelial Ovarian Cancer
por: Okunade, Kehinde S, et al.
Publicado: (2022)

p14 expression differences in ovarian benign, borderline and malignant epithelial tumors
por: Cabral, Vinicius Duarte, et al.
Publicado: (2016)

Chemokine expression in patients with ovarian cancer or benign ovarian tumors
por: Nowak, Marek, et al.
Publicado: (2021)

Role of tumour markers in monitoring epithelial ovarian cancer
por: Meyer, T, et al.
Publicado: (2000)

Benign and Suspicious Ovarian Masses—MR Imaging Criteria for Characterization: Pictorial Review
por: Valentini, A. L., et al.
Publicado: (2012)

Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings
por: Wilailak, Sarikapan, et al.
Publicado: (2015)

The Role of Preoperative Computed Tomography Radiomics in Distinguishing Benign and Malignant Tumors of the Parotid Gland
por: Xu, Yuyun, et al.
Publicado: (2021)

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours
por: Hunter, Sally M., et al.
Publicado: (2020)

Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
por: Mousavi, Azam-Sadat, et al.
Publicado: (2010)

Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer
por: Bednarska, Katarzyna, et al.
Publicado: (2018)

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors
por: Yun, Tae Hui, et al.
Publicado: (2022)

Quantitative analysis of the MRI features in the differentiation of benign, borderline, and malignant epithelial ovarian tumors
por: Xiao, Fuxia, et al.
Publicado: (2022)

Risk factors for benign ovarian teratomas.
por: Parazzini, F., et al.
Publicado: (1995)

Benign lesions that mimic cancer: Ovarian
por: Forstner, Rosemarie, et al.
Publicado: (2015)

Benign ovarian lesions with restricted diffusion
por: Agostinho, Lisa, et al.
Publicado: (2019)

Clinical utility of targeted treatments in the management of epithelial ovarian cancer
por: Twu, Cheryl, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6sm840f4rrm5uv7kor590gqqta